Literature DB >> 8016874

An evaluation of leflunomide in the canine renal transplantation model.

L P McChesney1, F Xiao, H N Sankary, P F Foster, S Sharma, M Haklin, J W Williams.   

Abstract

Leflunomide is an isoxazole with newly discovered immunosuppressive properties. Its mechanism of action operates later in the cell cycle than cyclosporine and appears to interfere with lymphocyte IL-2 responsiveness. With the encouraging results from in vitro and small-animal studies, we subjected leflunomide to the rigorous canine renal transplantation model in a dose response protocol. Thirty-eight female mongrel dogs underwent renal transplantation and bilateral nephrectomy. Immunosuppression was stratified from controls with no immunosuppression to monotherapy with leflunomide at 2, 4, 8, and 16 mg/kg/day given orally and in a combination therapy with cyclosporine. To evaluate its toxicity while maintaining a low constant blood level, eight dogs were treated by continuous intravenous infusion at doses of 2, 4, 6, and 8 mg/kg/day. The mean survival time for nonimmunosuppressed controls (n = 2) was 9 days, leflunomide 2 mg/kg/day (n = 2) was 9 days, leflunomide 4 mg/kg/day (n = 4) was 16 days, leflunomide 8 mg/kg/day (n = 5) was 28 days, leflunomide 16 mg/kg/day (n = 7) was 21 days. Cyclosporine alone at 10 mg/kg/day (n = 4) resulted in a mean survival time of 13 days. The mean survival time with the combination of cyclosporine 10 mg/kg/day with leflunomide 4 mg/kg/day (n = 6) was 68 days. The mean survival time for continuous intravenous leflunomide 2 mg/kg/day (n = 2) was 10 days; for leflunomide 4 mg/kg/day, 20 days; for leflunomide 6 mg/kg/day, 14 days; and leflunomide 8 mg/kg/day, 21 days. The mean serum trough levels of leflunomide ranged from 10 micrograms/ml at the 2 mg dose to 55 micrograms/ml for the 16 mg dose, levels that have been well tolerated in man. Leflunomide at 16 mg/kg/day reliably prevented acute allograft rejection, but the dogs died of inanition with normal renal function. Leflunomide at a nontoxic dose of 4 mg/kg/day extended survival to 16 days, but all dogs died of rejection. A combination of inadequate doses of leflunomide (4 mg/kg/day) and cyclosporine (10 mg/kg/day) resulted in all animals having normal renal function and weight for > or = 30 days. Even at a high dose of 16 mg/kg/day, no viral or bacterial infections were noted. These observations in a canine system add to the growing enthusiasm for the evaluation of leflunomide in human transplantation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8016874

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008).

Authors:  Sara A Colopy; Theresa A Baker; Peter Muir
Journal:  J Am Vet Med Assoc       Date:  2010-02-01       Impact factor: 1.936

2.  Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A.

Authors:  K Thoss; S Henzgen; P K Petrow; D Katenkamp; R Brauer
Journal:  Inflamm Res       Date:  1996-02       Impact factor: 4.575

3.  Tacrolimus enhances the immunosuppressive effect of cyclophosphamide but not that of leflunomide or mycophenolate mofetil in a model of discordant liver xenotransplantation.

Authors:  T Miki; A Goller; A Rao; X Wang; W Y Yin; A Tandin; J J Fung; T E Starzl; L A Valdivia
Journal:  Transplant Proc       Date:  1998-06       Impact factor: 1.066

Review 4.  Leflunomide: mode of action in the treatment of rheumatoid arthritis.

Authors:  F C Breedveld; J M Dayer
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 5.  Prevention of transplant rejection: current treatment guidelines and future developments.

Authors:  N Perico; G Remuzzi
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

6.  The active metabolite of leflunomide A771726 inhibits corneal neovascularization.

Authors:  Mingchang Zhang; Nian Hao; Fang Bian
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-06-19

7.  Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients.

Authors:  Nicolae Leca; Kimberly A Muczynski; Jonathan A Jefferson; Ian H de Boer; Jolanta Kowalewska; Elizabeth A Kendrick; Raimund Pichler; Connie L Davis
Journal:  Clin J Am Soc Nephrol       Date:  2008-03-27       Impact factor: 8.237

8.  A Retrospective Study on the Safety and Efficacy of Leflunomide in Dogs.

Authors:  M Sato; J K Veir; M Legare; M R Lappin
Journal:  J Vet Intern Med       Date:  2017-08-21       Impact factor: 3.333

9.  Synthesis, Physicochemical Characteristics and Plausible Mechanism of Action of an Immunosuppressive Isoxazolo[5,4-e]-1,2,4-Triazepine Derivative (RM33).

Authors:  Marcin Mączyński; Andrzej Regiec; Aleksandra Sochacka-Ćwikła; Iwona Kochanowska; Maja Kocięba; Ewa Zaczyńska; Jolanta Artym; Wojciech Kałas; Michał Zimecki
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.